DCR

es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel vs. lapatinib plus epirubicin and cyclophosphamide followed by docetaxel 1 -

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab
pertuzumab plus trastuzumab vs. trastuzumab 1 -
versus trastuzumab plus chemotherapy
trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy 1 -
versus trastuzumab plus docetaxel
pertuzumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel 2 -

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib
lapatinib plus trastuzumab vs. lapatinib 1 -
versus lapatinib plus capecitabine
neratinib plus capecitabine vs. lapatinib plus capecitabine 2 -
versus placebo
neratinib vs. placebo 1 -
versus trastuzumab plus capecitabine
lapatinib plus capecitabine vs. trastuzumab plus capecitabine 1 certainty unassessable+330%
tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine 2 -
versus trastuzumab plus vinorelbine
afatinib plus vinorelbine vs. trastuzumab plus vinorelbine 1 -